OVATF (Ovation Science) 5-Year EBITDA Growth Rate: 26.60% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ovation Science 5-Year EBITDA Growth Rate?

Ovation Science OVATF 5-Year EBITDA Growth Rate is 26.60% as of Mar. 2026. The stock has 4 warning signs investors should review.

Ovation Science's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 16.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 26.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ovation Science was 47.10% per year. The lowest was -40.80% per year. And the median was 16.10% per year.

Ovation Science  (OTCPK:OVATF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Ovation Science 5-Year EBITDA Growth Rate Related Terms

OVATF vs ZTS, UTHR: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovation Science 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ovation Science's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ovation Science's 5-Year EBITDA Growth Rate falls into.


Ovation Science 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 26.60% mean?
Ovation Science (OVATF) has a 5-Year EBITDA Growth Rate of 26.60% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Ovation Science and its competitors.
Is Ovation Science's 5-Year EBITDA Growth Rate too high?
Ovation Science's current 5-Year EBITDA Growth Rate is 26.60%.
How does Ovation Science's 5-Year EBITDA Growth Rate compare to ZTS and UTHR?
Ovation Science's 5-Year EBITDA Growth Rate of 26.60% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Ovation Science and its competitors. Ovation Science's current 5-Year EBITDA Growth Rate is 26.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Ovation Science (OVATF) has a current 5-Year EBITDA Growth Rate of 26.60%. The stock's GF Value™ is $0.04, compared to a current price of $0.04 — trading 12.5% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 26.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ovation Science (OVATF), the current 5-Year EBITDA Growth Rate is 26.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ovation Science Business Description

Other Exchanges OVAT:Canada
Address 1166 Alberni Street, Suite 1003, Vancouver, BC, CAN, V6E 3Z3
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.